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ABSTRACT 
Background: Multiple sclerosis (MS) is an immune-mediated disease where neurons in the 
central nervous system are demyelinated. Prevalence among women is twice as much as men and 
usually develops during childbearing years, causing concerns about the effects drug therapy may 
have on breastfeeding infants.   
Objective: To systematically review evidence regarding medications used to treat MS and to 
determine which are likely to be safe for use during breastfeeding.  
Methods: Web of Science and Pubmed databases were searched for publication dates between 
1950 and March 2016. Prescribing information on medications and reference lists of included 
articles were also searched. Each study was assessed using predetermined inclusion and 
exclusion criteria. Data were extracted based on study design, sample size, intervention, outcome 
measures, and results. 
Results: Literature indicates that interferon β, glatiramer acetate, prednisolone, methyl 
prednisolone, and immunoglobulin, are likely safe for use when breastfeeding, as medication 
levels present in human milk were insignificant and/or no adverse effects in infants were 
observed. However, natalizumab, mitoxantrone, alemtuzumab, fingolimod, and teriflunomide 
were all shown to be excreted in either human or animal milk. While no adverse effects on 
infants have been reported with these drugs, prescribing information does not recommend use 
while breastfeeding. It is unknown whether dimethyl acetate is excreted in either human or 
animal milk. Until more data are gathered, it is not recommended to use while breastfeeding. 
Conclusion: Overall, research on medication transfer through breast milk and adverse effects on 
infants is very limited. While there are some options for mothers with MS who wish to 
breastfeed, more research needs to be done to explore more options for them. 
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INTRODUCTION 
Multiple sclerosis (MS) is an immune-mediated disease where neurons in the central 
nervous system (CNS) are demyelinated.1 Demyelination occurs when macrophages and 
cytotoxic T cells cause chronic inflammation that subsequently causes damage to the myelin 
sheath that surrounds nerve cells. As a result, lesions form in the CNS, impeding the conduction 
of electrical impulses that control muscle groups.2 It is unknown exactly what causes this process 
to occur, however, it has been speculated that there may be more than one mechanism.1 MS is 
manifested by numerous and diverse symptoms which develop depending on the location of the 
lesions. Symptoms may be physical, with impairment of vision, speech, and/or muscle 
coordination, and may also affect cognitive function, causing issues such as memory loss and/or 
depression.2 Treatment is usually administered through immune-mediating drugs to help reduce 
relapses and slow progression of the disease.1 
There are multiple types of MS.1-3 The most common type is relapsing-remitting, which 
is when an individual suffers from decline after a period of recovery, but then improves and is 
symptom-free for a period before another relapse occurs.3 Symptoms usually develop over 
several days, stabilize, and then improve within weeks.1 Other forms of MS include primary 
progressive, secondary progressive, and progressive-relapsing.1,2 In primary progressive and 
secondary progressive MS, neurological function deteriorates over time. However, in primary 
progressive, they experience no early relapses, while those with secondary progressive usually 
start with initial relapses before steady decline eventually occurs. Progressive-relapsing MS is a 
rare form where the symptoms of the disease steadily worsen with no relapses but with acute 
exacerbations.2 MS commonly first occurs in early adulthood, between the ages of 20 and 30.1,2 
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About 2.3 million people have been diagnosed with this condition, with women being affected 
twice as frequently as men.1,2,4   
Because multiple sclerosis mostly affects women after the age of 20 and because this 
coincides with the childbearing years, maternal and infant health outcomes need to be 
considered. Historically, women with multiple sclerosis were discouraged from becoming 
pregnant.5 However, recent studies show that pregnancy does not exacerbate the long-term 
results of MS and may also be beneficial in reducing the frequency of relapses.2,5,6 Research has 
also shown that breastfeeding is not associated with postpartum relapses and may actually help 
reduce the frequency of postpartum relapses, especially in women who are not on disease-
modifying therapy.6-8 
The World Health Organization recommends that most infants are breastfed exclusively 
(receive no other foods or fluids) for 6 months after birth for optimal health benefits such as 
protection against infectious diseases and improvement of cognitive development.9 Breast milk 
also provides adequate nutrition for appropriate growth and development of their organs.10 
Importantly, breastfeeding may also be beneficial to maternal health, providing decreased risk 
for certain cancers and promoting optimal child spacing.9 These benefits extend to mothers with 
MS.2 Exclusive breastfeeding induces hormonal changes which in turn produce anti-
inflammatory results.2 Decreased inflammation prevents destruction of the myelin sheath, so the 
nerve cells are able to conduct electrical signaling normally.2,11  Despite these benefits for both 
mother and infant, when a lactating mother is taking disease-modifying medications, drug 
transfer through breast milk must be considered. While some medications are safe, not all are, 
and the decision must be made by carefully balancing the risk/benefit ratio between disease 
treatment and the benefits of breastfeeding.5 
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Drug exposure through breast milk consumption is an important area of study, as infants 
who are exclusively breastfed depend on this food source for all of their nutrient needs.10 If 
medications or other possible xenobiotic substances are in the milk in significant concentrations, 
they might interact with the physiological processes occurring in the infant’s body and inhibit 
growth or cause abnormalities.10,12 When studying the transport of these medications through the 
cells where milk is produced, which are mammary alveolar cells, many factors have to be 
considered including molecular weight, ionization, and carrier proteins.10,12 In addition to the 
characteristics of the medication compound itself, another major factor is plasma or serum levels 
in the mother.10 If she has high levels of the medication in her system, there is a chance that it 
will be high in milk as well, depending on the dosage administered and the ability of the 
mother’s body to absorb and/or metabolize it.10 These factors should be taken into consideration 
when a mother who needs drug therapy is contemplating breastfeeding.  
While there are several systematic reviews on use of medications during pregnancy and 
the postpartum period in women with multiple sclerosis, there are none that focus solely on use 
of these medications during lactation.13-15 The purpose of this review is to explore the literature 
on disease-modifying medications used in treatment of multiple sclerosis and consolidate the 
information in a comprehensive analysis of which medications are likely to be safe and which 
are contraindicated for use during breastfeeding.  
   
METHODS 
Search Strategy 
Web of Science and PubMed databases were searched to identify original research 
studies published between 1950 and March 2016. These dates were chosen because in 1950, after 
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World War II, scientists began making breakthroughs in research, contributing to much of what 
is known about MS today.16 The following keywords were used in both database searches to find 
relevant articles: “multiple sclerosis”, “drug”, “breastfeeding”, “breast feeding”, “lactation”, 
“interferon”, “glatiramer acetate”, “natalizumab”, “mitoxantrone”, “alemtuzumab”, 
“fingolimod”, “teriflunomide”, “dimethyl fumarate”, “prednisolone” and “intravenous 
immunoglobulin”. These medication names were determined by reviewing the medications page 
of the National Multiple Sclerosis Society’s website.17 All medication names are the generic 
version. The reference lists of identified review articles cited by other articles at least five times 
in original research articles, were searched to identify additional studies related to drug therapy 
for MS that were not discovered in the original key word search.  In addition, prescription 
information on all medications found on the National Multiple Sclerosis Society’s website was 
examined.17   
Study Selection 
 Inclusion criteria included 1) having lactating females (human or animal) as subjects, 2) 
evaluation of an MS drug therapy intervention, and 3) reported outcomes of serum, plasma, or 
breast milk levels of the medication (maternal or infant) and/or report of side effects in infants. 
Exclusion criteria included 1) not an original research article and 2) not available in English. 
Articles were either retrieved directly from the Web of Science or Pubmed databases or were 
obtained from the interlibrary loan service of the University of Tennessee, Knoxville. The titles 
and abstracts of all articles were reviewed and compared against the inclusion and exclusion 
criteria. If no abstract was available or if the abstract was lacking sufficient information, the full 
article was examined. Citations in review articles were used to identify additional original 
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research studies that met the inclusion criteria. Articles were excluded if they were a duplicate of 
a previously-selected publication.  
Data Extraction 
Data were extracted regarding study design, sample size, intervention, outcome measures, 
and results. Outcomes of interest included levels of drugs excreted in milk and effects on 
breastfed infants.  
RESULTS  
 The preliminary search using the identified key terms yielded 69 unique articles (38 from 
Web of Science; 31 from Pubmed). However, 33 of these were review articles, 6 were not 
available in English, 2 were commentaries, and 1 article was no longer available on the website 
(the only identified location of the article). The remaining 21 articles were reviewed for relevant 
outcome measures. Only 5 of these 21 evaluated breast milk levels of the medication and/or 
report side effects in infants. When reference lists of review articles were searched, 4 additional 
articles meeting the inclusion criteria were identified. These 9 articles, along with specific 
characteristics of each, are outlined in the Table. In addition to these 9 articles, prescription 
information was included for all medications identified on the National Society of Multiple 
Sclerosis website. This review categorizes the medications by type: injectable, infused, oral, and 
other. 
Table. Summary of studies found on disease-modifying medications used for multiple 
sclerosis during lactation 
Author(s) 
Medication 
Evaluated 
Sample Size Outcome Measure 
Hale et al.18 Interferon β 6 Medication level in breastmilk 
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Salminen et al.19 Glatiramer acetate 13 Side effects on infants 
Fragoso et al.20 Glatiramer acetate 11 Side effects on infants 
Baker et al.21 Natalizumab 1 Medication level in breastmilk 
McKenzie et al.22 Prednisolone 7 Medication level in breastmilk 
Cooper et al.23 Methylprednisolone 1 Medication level in breastmilk 
Greenberger et al.24 Methylprednisolone 3 Medication level in breastmilk 
Strijbos et al.25 Methylprednisolone 1 Medication level in breastmilk 
Achiron et al.26 Immunoglobulin 79 Side effect on infants 
 
Injectable Medications 
Interferon Beta 
 Interferons are a class of proteins that are usually produced by lymphocytes when 
bacteria, viruses, or other parasites invade the body, and these proteins are believed to down-
regulate the autoimmune response that occurs in MS.18 The mechanism of action is not yet fully 
understood.18 However, it is known that these proteins take part in anti-proliferative and 
immunomodulatory actions, meaning that they inhibit cell growth and alter the immune 
response.18 It is the most commonly used immunomodulatory drug for treatment of MS.19 There 
are three major types of interferons, but only interferon β has been used in the clinical setting for 
MS.18 Due to its large molecular size, a characteristic that has shown to decrease drug transfer to 
milk, interferon β was researched by scientists to determine if its use could be continued in 
patients with MS who desire to breastfeed.10 The medication has to be injected subcutaneously 
three times per week and therefore may present a significant burden to a mother trying to 
breastfeed her infant.27 
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In one observational study18, six women with MS volunteered to collect their breast milk 
and allowed it to be analyzed. The subjects had been receiving a dose of 30 µg of interferon β 
intramuscularly every week for at least one month. The first sample collected served as the 
control. Mothers collected samples of their milk at 1, 4, 8, 12, 24, 48, and 72 hours post-
injection.  Each breast was pumped for 12 minutes with an electric breast pump to assure 
collection of both fore and hind milk. The samples from each breast were pooled and then sent to 
the lab.  
 For their method of measurement, an enzyme-linked immunosorbent assay, there was a 
limit of detection of 20 pg interferon β/mL.18 Many of the specimens obtained had 
concentrations of interferon β-1a below this level. Each mother provided 8 samples, however, the 
medication was not detected in all of these, indicating variability between and among mothers. 
For example, no medication was detected in any of the 8 samples from one mother, while it was 
detected in 2 of the 8 samples from another mother, and in 3 of the 8 samples from another 
mother. Therefore, some mothers had more samples to compare against than others. The 
detectable amounts ranged from 32.9 pg/mL to 179 pg/mL. Using the maximum level detected 
(179 pg/mL), the researchers calculated the relative infant dose and found that it would only be 
0.006% of the maternal dose. At the end of the study, none of the subjects reported any adverse 
effects in their infants while breastfeeding.18 The authors suggest that for doses that are typically 
provided for those with MS, the levels of interferon β-1a that are passed through human milk are 
likely to be inconsequential and are unlikely to cause harmful effects on breastfeeding infants. 
 Since the subjects were not supervised when pumping their milk, there might have been 
some inaccuracy in the data.18 The mothers were in control of when they obtained their samples 
and may not have followed the desired schedule, possibly skewing the results by having 
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significantly different levels of drug in their breast milk than the other mothers during the same 
time interval. A limitation of this study is that it followed a small sample of women over a short 
period of time, inhibiting the generalizability of the study. The strongest study design that would 
provide stronger evidence would be a randomized control trial (RCT) conducted over a longer 
period.28 However, this is not plausible as breastfeeding is a personal choice and it is unethical to 
tell a mother to breastfeed or not. The article states that this is the first study that has attempted to 
quantify the transfer of interferon β into breastmilk.18 Since no other study on this topic was 
found in the literature search, this is likely to be the only evidence available that provides any 
support that interferon β can be used while a mother is breastfeeding. However, it is important to 
note that the prescribing information for interferon β  reports that is not recommended.29 
Glatiramer acetate 
 The mechanism by which glatiramer acetate, a synthetic polymer, acts to treat MS is not 
completely understood.30 However, it is speculated that it binds to major histocompatible 
molecules in order to produce secretion of anti-inflammatory cytokines.30 Glatiramer acetate can 
be administered either every day, at 20 mg/mL, or three times per week, at 40 mg/mL.31 This 
frequency may be an important consideration for those wanting to breastfeed. In this systematic 
search, no studies were found that measured glatiramer acetate concentrations in breast milk. 
Therefore, to gain more insight into the possible safety of using this medication while 
breastfeeding, two retrospective evaluations of women with MS who were treated with 
glatiramer acetate during pregnancy and the effect on their infants were reviewed.19,20  
 In one case series, thirteen women with MS who were taking glatiramer acetate as 
treatment were asked to come in for a systematic follow up after their pregnancies. However, the 
authors only report on infant feeding mode for 12 women, with 2 breastfeeding (one for 2 
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months and the other for 6 months), six breastfeeding for less than 2 weeks, and the remaining 4 
not breastfeeding at all. It is unknown why there was nothing reported for the 13th mother. At the 
end of the study, the researchers reported observing no drug-related outcomes for the mothers or 
infants and none of the mothers who breastfed reported any unusual behavior or activity from 
their infants.19 However, the authors did not report when the follow-up occurred, therefore, it is 
not possible to determine length of exposure and/or timing of observation of the infants. 
 In another case series, conducted in Brazil, eleven women with clinically diagnosed MS 
and their children were retrospectively assessed.20 These women had received glatiramer acetate 
consistently for at least 7 months of their pregnancies. Of these eleven women, nine breastfed 
their infants, and did so for an average of 3.6 months. No infections, developmental issues, or 
other significant negative effects were observed in the children by their mothers. While there was 
one case of neonatal infection, it was not considered to be drug induced.20  
 While these case series did not specifically survey medication levels in milk, the effect on 
exposed infants is something to take into consideration when determining drug safety. Since no 
injurious symptoms were exhibited by the breastfed children, there is some evidence that 
glatiramer acetate, if passed through human milk, is likely not excreted at high enough levels to 
cause complications. However, there are limitations to these studies since they are only case 
series and cannot prove cause and effect and maternal observation of infant behavior could 
introduce bias.28 Neither study had a control group that allowed for comparison against the 
women and infants exposed to glatiramer acetate. In addition, review of prescribing information 
indicates that glatiramer acetate is not recommended while breastfeeding.31 
Infused Medications 
Natalizumab 
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 Natalizumab is a recombinant humanized IgG4 monoclonal antibody and is categorized 
as a selective adhesion molecule inhibitor.21 Natalizumab acts to inhibit activation, migration, 
and function of leukocytes in areas of inflammation by blocking them from attaching to the α4-
integrin molecule. This helps decrease the frequency of relapses in inflammatory diseases such 
as MS.21 Natalizumab is typically infused at 300 mg intravenously for about one hour, every four 
weeks.32 Breastfeeding women may find this relatively low frequency attractive. However, the 
limited research on this medication inhibits the ability to assess the safety of its use during 
breastfeeding. 
Only one article was found that examined the transfer of natlizumab into breast milk.21 In 
this case report, a 28-year old female with MS started drug therapy while breastfeeding her 
infant. She was given the typical dosage of 300 mg IV which was infused over 1 hour every four 
weeks. Milk samples were collected 3 weeks before treatment was initiated and then collected 
every day after her first dosage over the following 50 days. She received a second dosage on day 
29.  The levels of natalizumab in the milk were then measured, allowing the researchers to see 
how long the drug would be excreted in milk over the course of about two weeks. 
 The noncompartmental pharmacokinetic method of assessment, utilized in this study, is 
capable of detecting levels of natalizumab at or above 0.25 µg/mL.21 During the first 13 days 
after the first infusion, the concentration of natalizumab in the milk was undetectable. However, 
on day 14, levels were detected at a concentration of 0.33 µg/mL. From day 15 to 28 levels 
fluctuated between 0.339 and 1.008 µg/mL, but remained relatively low. Interestingly, after day 
29 the concentration began to rise daily, reaching a maximum amount of 2.83 µg/mL on day 50. 
This may indicate that natalizumab levels in breast milk continue to escalate. 
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Two methods were used to calculate the relative infant dose (concentration-time curve 
and breast milk concentration).21 The area under the concentration-time curve estimated the 
relative infant dose to be 1.74%, while the average concentration in milk calculation resulted in 
an estimate of 5.3%.21 The authors report that, generally, a dose less than 10% is considered safe 
for a breastfeeding infant.21 Therefore, both of the doses calculated above were well below this 
safe level. However, the researchers were concerned that levels of natalizumab in milk would 
continue to escalate to possibly toxic levels past the 50 day mark. While these results indicate 
that breastfeeding might be safe to do for a certain amount of time, it should be considered that 
continuous use of natalizumab could cause increased amounts to be transferred through milk as 
the drug collects in the milk ducts.21 A long-term study, and ideally an RCT, would be beneficial 
in exploring the concerns raised by this case report, as a case report is generally considered to be 
a weak study design.28 The prescribing information reports that natalizumab can pass through 
milk, but that it is unknown whether or not it is harmful for infants.32 Interestingly, there is no 
statement of contraindication of use during breastfeeding, only the emphasis on mothers who are 
planning to breastfeed communicating with their physician that they are on this medication.32 
Mitoxantrone 
 Mitoxantrone is a cytotoxic, antineoplastic agent and immunomodulatory drug.33 It is 
usually given once every three months for about two to three years through an infusion that takes 
about five to 15 minutes to administer.34 This relatively low frequency may be especially 
attractive to breastfeeding women. The mechanism of action includes activating macrophage-
mediated suppression of B-cell, T-helper, and T-cytotoxic lymphocyte function. Mitoxantrone 
also inserts into DNA which prevents DNA strands from coming together, slowing the cell-cycle 
progression. Levels of mitoxantrone have been found to remain in tissue for extended periods of 
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time, suggesting that it is slow to be eliminated from the body. For example, an autopsy found 
measurable levels in tissue from a patient who had received the dosage up to 272 days before 
death.33 
Searching the databases using the relevant key terms yielded no research evaluating 
mitoxantrone secretion in breast milk. Related reviews were examined for sources to determine 
current recommendations.13-15 The prescribing information provided by the Food and Drug 
Administration (FDA) reports evidence that mitoxantrone is excreted in breast milk and that high 
concentrations (18 ng/mL) of the drug have been found in milk 28 days post-infusion.34  
Although data are extremely limited on this drug, the likelihood that mitoxantrone is slow 
to be eliminated from the body could be an indication that this drug is not the safest to use while 
breastfeeding. Elevated levels in the maternal plasma are likely to be mirrored in breast milk and 
could result in adverse effects for a breastfed infant.10 In fact, the FDA does not recommend that 
women take mitoxantrone and breastfeed at the same time.34 Women attracted to the relatively 
low frequency of dose, who are considering breastfeeding, should be informed about the FDA 
recommendation and should not breastfeed if using this medication. 
Alemtuzumab 
 Alemtuzumab is a humanized monoclonal antibody, for which the mechanism of action is 
not completely understood.35 However, there is some indication that it targets cell surface 
proteins on lymphocytes and monocytes and is connected to T-cell migration and co-stimulation. 
Alemtuzumab eliminates CD52+ tumor cells and is involved in the initiation of apoptosis.35  
No literature was found evaluating the excretion of alemtuzumab into breast milk. 
Prescribing information does not  provide information on whether it is transferred into human 
milk, however,  similar compounds have shown to be able to do so.36,37 Prescribing information 
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also states that alemtuzumab is excreted in the milk of lactating mice.36,37 The lack of 
information on this drug could be that it is relatively new, compared to the other disease-
modifying drugs used for multiple sclerosis. 
Alemtuzumab is administered through an IV infusion over two hours three times per 
week for about 12 weeks.36 Therefore, it is likely to present a significant burden to a mother with 
a young infant, regardless of infant-feeding mode. Due to the frequency of the dosage and the 
lack of knowledge about adverse effects on infant health, mothers with multiple sclerosis should 
probably not breastfeed while on this medication. 
Oral Medications 
Fingolimod 
 Fingolimod is a sphingosine 1-phosphate receptor modulator.38 It works by first being 
phosphorylated and then binding to a series of different molecules to ultimately reduce 
inflammation and aid in the repair of the central nervous system. Fingolimod may also be able to 
help treat chronic infections.38 It is recommended to be taken orally once a day.39 
Searching the databases yielded no studies on fingolimod use during breastfeeding or 
measurement of fingolimod expression in human milk. However, prescribing information 
indicates that fingolimod has been detected in the milk of lactating rats.40 In treated animals, 
levels of the drug have found to be 2-3 times higher than levels found in the plasma of the 
mother.39 There appears to be no publicly available information regarding adverse effects on 
infants, however, both the FDA and EMA (European Medicines Agency) recommend that 
women who are being treated with fingolimod do not breastfeed or that they discontinue therapy 
if they choose to breastfeed.39,40 
Teriflunomide 
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 Teriflunomide is a high affinity inhibitor of dihydroorotate dehydrogenase which is a key 
enzyme in the production of pyrimidine.41 Pyrimidine is needed by fast proliferating cells, like 
lymphocytes, to meet DNA, lipid, and glucose metabolism needs. Teriflunomide is unique, 
however, in that it is selectively active and only targets proliferating lymphocytes.41 This is 
beneficial because there is no concern that it will attack non-malignant cells, causing other 
adverse symptoms. Teriflunomide tablets (7mg or 14mg) should be taken daily, with the dose 
depending on severity of disease.42 
Similar to the previous three drugs, no research was found on teriflunomide and transfer 
during lactation. However, prescribing information reveals that teriflunomide has been detected 
in the  milk of lactating rats after receiving a single dose.42,43 Therefore, it is advised that mothers 
should either cease breastfeeding or stop taking teriflunomide, depending on the how significant 
the drug is to the mother’s health.42,43  
Dimethyl fumarate 
 Dimethyl fumarate is an oral therapeutic agent that reduces both disease activity and 
progression in relapsing-remitting MS, as it functions through multiple pathways.44 For example, 
dimethyl fumarate is able to inhibit immune cells and may have anti-oxidant properties that help 
prevent damage to the brain or spinal cord.44 This medication begins with 240 mg capsules taken 
twice a day for seven days, but then increases to a dosage of 240 mg twice a day.45 
Information on dimethyl fumarate is extremely limited.45,46 It is unknown whether 
dimethyl fumarate is excreted in breast milk. The prescribing information does not provide any 
information on milk transfer, in humans or other animals.45,46 This may be because this 
medication is also still relatively new, having been released three years prior to this review.47  
Other Medications 
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Corticosteroids 
 Corticosteroids are often used to quickly mitigate relapses.1 They can be administered 
either orally (prednisolone) or intravenously (methylprednisolone) for management of 
exacerbations.17,48,49 The most common treatment used for MS is a high-dose intravenous 
administration of methylprednisolone, which has potent anti-inflammatory and 
immunosuppressive effects over three to five days.17,23 This intravenous dose is typically 
followed by an oral dosage of prednisolone that gradually tapers off over the course of ten days 
to six weeks.49 A high oral dose may also be used if intravenous administration is not desired or 
if it is contraindicated.49 The dosage and frequency of administration varies, however, depending 
on the severity of the disease.48,49 
It appears that the transfer of steroids into breast milk has been studied to a much greater 
extent than other MS therapies. For example, the earliest study found in this review was 
published in 1975 and analyzed prednisolone levels in the milk of seven lactating mothers for 48 
hours after an oral dosage of 5mg.22 Milk was expressed via breast pump at different intervals, at 
which point it was analyzed by liquid scintillation using oxidation. The results showed that the 
highest level of prednisolone in the milk was found in the first sample from each mother, ranging 
from 0.23% to 0.52% per liter of milk, but then declined at a rapid rate, reaching a plateau after 
24 hours. The researchers concluded that if an infant were to nurse from a mother taking 30 mg 
of prednisolone a day, the amount that would be transferred through the milk would be 
minuscule.22  
 In the remaining three studies, prednisolone was administered through an intravenous 
injection rather than via the oral route.23-25 In one study, three women were given 50 mg 
prednisolone phosphate through an IV line over 10 seconds.24 For 6 hours post-injection, the 
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women used a breast pump to retrieve milk from alternate breasts every hour until empty, after 
which the samples were analyzed. An average of 0.025% of the administered prednisolone was 
recovered in the milk.24 This percentage is very low when compared to the 10% cut off that is 
considered safe for breastfeeding, which is stated by the authors. 
The second study followed a 36-year old female who received a standard dose of 1000 
mg IV methylprednisolone sodium succinate over 2 hours on 3 consecutive days.23 She collected 
her breast milk at 0, 1, 2, 4, 8, and 12 hours after the dosage each day. The samples were then 
analyzed for drug concentration. The relative infant dosage was calculated to be 1.45%, 1.35%, 
and 1.15% for days 1, 2, and 3, respectively. Compared to the theoretical level of concern for 
medications in breast milk (>10%), these levels are relatively low.23  
A very similar study was conducted on a 39-year old patient with MS.25 She received a 
dose of 1000 mg/day of methylprednisolone and milk samples, taken at 4 hours and 8 hours post-
dosage, were screened through chromatography. Researchers found that when comparing 
methylprednisolone levels at 4 hours and 8 hours after the injection, drug concentration was 
significantly decreased at the 8 hour mark from 3.0 mg/L to 0.048 mg/L. Therefore, they 
concluded that it is safe to breastfeed while on this drug but recommend that a mother wait 8 
hours after taking methylprednisolone to breastfeed her infant.25 This, however, would mean that 
the mother would have to carefully plan pumping her milk around her treatment. For the typical 
treatment regime that lasts over three to five days, this could be difficult to do, especially if the 
mother has frequent acute exacerbations. 
Since the literature identified consisted only of case reports/case series, the strength of 
evidence for this medication is weak and completion of one or more RCTs would help to 
increase understanding of risk to breastfed infants. However, medications that are given through 
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IV are likely to be higher in breast milk, as opposed to those taken orally. Since two studies 
showed that the infant dosage delivered by a mother receiving an IV dose of methylprednisolone 
is relatively low, the oral form of prednisolone is even less likely to cause adverse effects in 
infants.23,24 This means that if a mother did not want to receive IV therapy, oral prednisolone is a 
viable alternative for treating relapses and is likely to be safe for use during breastfeeding.49 
However, prescribing information for methylprednisolone does not provide any information on 
milk transfer in humans or any animals, and women should always consult with their healthcare 
provider to plan an appropriate course of action.50  
Intravenous immunoglobulin 
 Intravenous immunoglobulin is an antibody that has several different mechanisms used to 
modulate the immune system.51 It can inhibit the binding of pathological antibodies and may be 
able to assist with remyelination.51 The dose of intravenous immunoglobulin also depends on the 
severity of the condition, but can be administered every 3-4 weeks.52 
There were no studies identified that specifically looked at immunoglobulin levels in 
breast milk. However, in a retrospective evaluation, three groups of pregnant women with 
relapsing-remitting MS were studied for relapse rate and the effect of the drug during pregnancy 
and the postpartum period.26 The first group consisted of women who received a dose of 0.4 g/kg 
body weight/day for 5 consecutive days within the first week after delivery, and additional 
booster doses of 0.4 g/kg body weight/day at 6 and 12 weeks postpartum. The second group was 
treated continuously with IV Ig during the gestation and postpartum periods (0.4 g/kg body 
weight/day). This included a period of 5 consecutive days within the 6-8 weeks of gestation then 
additional booster doses of 0.4 g/kg body weight/day were administered once every 6 weeks 
until 12 week postpartum. The final group received no treatment. Assessment of breastfeeding 
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behavior was not an objective of this study. However, the authors reported that about 73% of the 
infants were breastfed for at least 3 to 12 weeks and that no adverse effects were observed in 
these infants.26 
Research done specifically on immunoglobulin levels in breast milk would provide better 
evidence for safety of use during breastfeeding. This strongest evidence would be provided by a 
RCT.28 Prescribing information provides no information on transfer into human or animal milk 
and does not provide a statement on use during breastfeeding.53 Therefore, mothers should 
consider this gap in research when planning to breastfeed. 
 
DISCUSSION 
 This systematic review of original research investigating the use of MS medications 
during lactation identified a significant gap in the literature. What research has been completed 
indicates that, of the ten drugs identified as being used for treatment of MS, only four were found 
to be safe to use during lactation: interferon β, glatiramer acetate, prednisolone, and 
immunoglobulin.18-20,22-25 Despite their likely safety, both interferon β and glatiramer acetate are 
still only given a lactation risk category of L3 by Dr. Thomas Hale, the executive director of the 
Infant Risk Center, meaning they are considered to be moderately safe to use in this situation.54,55 
Prednisolone and immunoglobulin have a lactation risk category of L2, which means they are 
considered safer to use during breastfeeding than medications in the L3 category but have only 
been studied in a limited number of breastfeeding women.55 Since natalizumab, mitoxantrone, 
alemtuzumab, fingolimod, and teriflunomide are all shown to be excreted in milk, they are 
considered possibly hazardous and/or are contraindicated during lactation, even though there is 
no evidence of adverse effects in infants.55 Since it is unknown whether dimethyl fumarate is 
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excreted in either human or animal milk, there is no lactation risk category assigned. However, 
even with the abundance of drugs that are contraindicated during lactation, it is not 
recommended that mothers avoid breastfeeding altogether.56 Most mothers with MS are 
encouraged to breastfeed if they are able to withstand discontinuing their drug therapy for the 
duration of their lactation experience.56  
Limitations 
The research completed on the transfer of drugs into breast milk is very limited. Overall, 
there is a paucity of published reports that confirm risk of adverse effects to infants.57 While 
there are some studies that imply safety of use for certain medications, randomized control trials 
would provide much stronger evidence for these claims. However, randomized control trials 
generally cannot be conducted due to the ethical issue of randomizing a mother to breastfeed or 
formula feed. The drug component of the studies causes more issues, as the type of drug, dosage, 
and frequency of dosage would be dependent on the type and severity of the mother’s MS. 
Administering a standard dose could be detrimental to the mother’s health if she requires more 
than this amount. Also, since it has been found that natalizumab, mitoxantrone, alemtuzumab, 
fingolimod, and teriflunomide are excreted in milk, it is unethical to allow infants to receive 
breast milk from mothers taking these drugs, as it is unknown how this might impact infant 
health and well-being. The studies that have been conducted also have very small sample sizes, 
which makes it more difficult to generalize to other populations. Due to these ethical barriers, 
most instructions on safe drug use during lactation are based on case reports or single case 
studies that measure breast milk or infant serum drug levels, resulting in decisions made based 
on weak study designs57 
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One limitation of this systematic review is that articles not available in English were not 
included. Both time constraints and lack of access to translation services prevented use of these 
articles. Another limitation, for systematic reviews in general, is that studies that have more 
impressive results are more likely to be published and subsequently identified by other 
researchers, meaning there is some element of publication bias present.58 Finally, relevant 
information might have been excluded, secondary to the choice of key words.  
Context 
Other literature reviews on maternal to infant drug transfer have often focused on 
medication use during pregnancy (maternal-fetal transfer), due to the abundance of research in 
this area. While breastfeeding information is usually included in these articles, this review is 
unique in that the goal was to focus solely on breastfeeding. In doing so, it has highlighted the 
lack of research that has been completed on this topic within the search time span of 1950-2016. 
The studies identified by this systematic search were the same studies included in other 
systematic reviews completed on this topic. The lack of new literature indicates a need for more 
studies to be conducted, specifically for mitoxantrone, alemtuzumab, fingolimod, teriflunomide, 
and dimethyl fumarate, information for which all came from prescribing information, likely due 
to the absence of any other available sources. 
Future Direction 
Research has shown that most medication given to a mother will pass to a breastfeeding 
infant, with the exception of those with large molecular weight.59 This means that the real 
concern is not if a medication is excreted, but how much of it is excreted and if that amount 
poses a risk to the infant. In order to establish the risk of a drug to a neonate, it is important to be 
able to predict the amount of the drug presented to the infant following administration via milk.59 
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More detailed research studies, specifically on the drugs mitoxantrone, alemtuzumab, fingolimod, 
teriflunomide, and dimethyl fumarate, need to be organized in order to determine fully if these 
drugs should remain contraindicated for use during breastfeeding.  While these drugs are 
excreted in milk, that alone does not provide a definitive reason to avoid breastfeeding.  
Report of adverse effects in literature does not necessarily define an absolute 
contraindication, but does implore the use of caution when using drugs, by monitoring the infant 
for both physical and behavioral changes.57 Breastfeeding has been shown to be beneficial for 
infants for both cognitive and immune system development.9 If mothers with MS are able to 
breastfeed without giving up medication they need, infants will be better able to gain the full 
advantages of breast milk without forfeiting the well-being of the mother. However, until these 
drugs can be explored further, mothers should evaluate the benefits of breastfeeding against the 
benefits of their drug therapy and consult their doctor about determining whether they should 
breastfeed, continue their medication, or switch to another disease-modifying drug which is safer 
to use while breastfeeding. 
 
CONCLUSION 
 Only four medications used in the treatment of MS are considered safe to use while 
breastfeeding. Interferon-β, glatiramer acetate, and prednisolone are not secreted in human milk 
at significant levels and no adverse effects in infants have been found. While it is not known 
whether intravenous immunoglobulin is secreted in breast milk, it has not been shown to cause 
detrimental side effects in infants. Natalizumab and mitoxantrone are excreted in human milk, 
but it is unknown whether they cause any harm. Fingolimod and teriflunomide have been found 
to be excreted in rodent milk while alemtuzumab has been found to be excreted in murine milk. 
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It is unknown whether dimethyl fumarate is excreted in the milk of either of these species. 
Natalizumab, mitoxantrone, fingolimod, teriflunomide, alemtuzumab, and dimethyl fumarate are 
not recommended to use while breastfeeding. However, this recommendation appears to be due 
more to lack of research and considerable precaution with infant health than with results of 
carefully planned and implemented studies. 
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